ENTASIS THERAPEUTICS, INC.

• TRUSTEES OF BOSTON UNIVERSITY

  UEI THL6A6JLE1S7

  $269.5K

  Subcontractor to this prime · 1 sub-award · latest Jul 17, 2026

  • Office of Assistant Secretary for Preparedness and Response
  • “THIS PROJECT SUPPORTS THE EARLY DEVELOPMENT OF ETX1791, A NEW INVESTIGATIONAL ANTIBIOTIC DESIGNED TO TREAT SERIOUS INFECTIONS CAUSED BY DRUG-RESISTANT GRAM-NEGATIVE BACTERIA. THESE INFECTIONS ARE A GROWING GLOBAL HEALTH THREAT AND ARE INCREASINGLY DIFFICULT TO TREAT WITH EXISTING MEDICINES. ETX1791 IS A DERIVATIVE OF ETX0462, A MOLECULE THAT HAS PREVIOUSLY SHOWN STRONG ACTIVITY AGAINST A BROAD RANGE OF CLINICALLY IMPORTANT GRAM-NEGATIVE BACTERIAL PATHOGENS. THE GOAL OF THE CURRENT PROGRAM IS TO ANSWER A FOCUSED SET OF KEY QUESTIONS NEEDED TO FURTHER CHARACTERIZE ETX1791 AND INFORM FUTURE DEVELOPMENT PLANNING. THIS WORK WILL GENERATE ESSENTIAL DATA ON ACTIVITY AGAINST CURRENT CLINICAL BACTERIAL STRAINS, EFFICACY IN ANIMAL MODELS OF INFECTION, AND POTENTIAL FOR CLINICAL DEVELOPMENT. THE PROGRAM INCLUDES SEVERAL COORDINATED ACTIVITIES TO: --CONFIRM THAT ETX1791 CAN BE PRODUCED AND HANDLED APPROPRIATELY FOR DEVELOPMENT. --EVALUATE ITS EFFECTIVENESS AGAINST A LARGE AND RECENT COLLECTION OF CLINICALLY RELEVANT BACTERIAL PATHOGENS. --UNDERSTAND HOW THE DRUG IS PROCESSED IN VIVO AND CONVERTED TO ITS ACTIVE FORM. --ASSESS WHETHER IT CAN BE GIVEN BOTH INTRAVENOUSLY AND AS AN ORAL TREATMENT, WHICH COULD ALLOW PATIENTS TO TRANSITION FROM HOSPITAL-BASED TO OUTPATIENT CARE. THESE STUDIES ARE DESIGNED WITH CLEAR SUCCESS CRITERIA SO THAT DEVELOPMENT DECISIONS CAN BE MADE EFFICIENTLY. AT THE END OF THIS WORK, THE PROJECT WILL DELIVER A COMPREHENSIVE DATASET THAT HELPS DEFINE THE DRUG’S POTENTIAL USE, SUPPORTS ITS TARGET PRODUCT PROFILE, AND INFORMS NEXT STEPS FOR MORE ADVANCED PRECLINICAL AND CLINICAL EVALUATION. OVERALL, THIS PROGRAM AIMS TO ADVANCE A PROMISING NEW ANTIBIOTIC CANDIDATE THAT COULD ADDRESS URGENT UNMET MEDICAL NEEDS AND HELP COMBAT THE GROWING CHALLENGE OF ANTIBIOTIC RESISTANCE.”

No reported sub-awards as a prime contractor.

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.